{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-044022","form_type":"8-K","ticker":"PPCB","cik":"0001517681","company_name":"Propanc Biopharma, Inc.","filed_at":"2023-12-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.343509+00:00","generated_at":"2026-06-07T16:09:00.360001+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Propanc Biopharma issues $45K convertible note with 35% discount conversion","bullets":["Principal $45,000; maturity Sept 15, 2024; interest 8% (22% default); issued to 1800 Diagonal Lending LLC.","Conversion price at 35% discount to avg of lowest 3 trading prices over 10 days prior; 4.99% beneficial ownership cap.","Company may prepay within 180 days at escalating premiums: 110% to 129% of principal plus interest.","Proceeds for general working capital; company also pays $5,000 buyer's legal/due diligence fees.","Note issued under Section 4(a)(2)/Reg D private placement exemption."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-044022","json":"https://secwatch.observer/filing/0001493152-23-044022.json","markdown":"https://secwatch.observer/filing/0001493152-23-044022.md","text":"https://secwatch.observer/filing/0001493152-23-044022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223044022/0001493152-23-044022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223044022/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T16:09:00.360001+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"76747f989180d9690aaa96b3aa69cfc61f3e50e2","claim":"Propanc Biopharma, Inc. entered into Purchase Agreement with an investor valued at $45,000 (effective 2023-12-04).","evidence_excerpt":"Effective December 4, 2023, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $45,000 (the “Note”), for a purchase price of $45,000.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223044022/0001493152-23-044022-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an investor"},{"label":"Value","value":"$45,000"},{"label":"Effective","value":"2023-12-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}